Business
Adagio Medical Provides Clinical and Business Updates
LAGUNA HILLS, Calif., March 17, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the "Company"), a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia ("VT") solutions.
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"LAGUNA HILLS, Calif., March 17, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the "Company"), a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia ("VT") solutions.","length":313,"tagName":"p"},{"type":"text","content":"Recent Business Highlights:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company will participate in the scientific program of the 2025 European Heart Rhythm Association (the "Association") Annual Meeting to be held from March 30 through April 1 in Vienna, Austria.","length":206,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"At the Association’s Ablation Innovation Summit, Dr. Tom De Potter, MD, PhD Associate Director, Cardiovascular Center at AZORG hospital in Aalst, Belgium will deliver a lecture on the use of the Company’s proprietary ultra-low temperature cryoablation ("ULTC") technology for treatment of scar-related monomorphic ventricular tachycardia.","length":348,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In addition, Professor Mark Gallagher, MD from St. George’s University Hospital in London, UK, will present a first-in-human case series using ULTC for ablation of premature ventricular complexes ("PVC"). The ablations of idiopathic PVCs constitute over half of current VT ablation cases. ULTC uniquely addresses some of the procedural challenges associated with these ablations.","length":389,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":737,"olType":false}]},{"val":[{"type":"text","content":"The Company announced that the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia, NCT05675865) IDE Pivotal Study is over 40% enrolled. The trial, designed to support US premarket approval of the VT Cryoablation System with the vCLAS™ catheter is on track for completion of full patient enrollment in the second half of 2025. FULCRUM-VT is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory ventr...